Teva Pharmaceutical Industries Limited vs Taro Pharmaceutical Industries Ltd.: A Gross Profit Performance Breakdown

Teva vs. Taro: A Decade of Gross Profit Trends

__timestampTaro Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 201458000600011056000000
Thursday, January 1, 201567658500011356000000
Friday, January 1, 201677896600011859000000
Sunday, January 1, 201767125100010825000000
Monday, January 1, 20184635080008296000000
Tuesday, January 1, 20194457240007536000000
Wednesday, January 1, 20203997250007725000000
Friday, January 1, 20212966560007594000000
Saturday, January 1, 20222931220006973000000
Sunday, January 1, 20232683230007646000000
Monday, January 1, 20243049790008064000000
Loading chart...

Unlocking the unknown

A Tale of Two Pharmaceutical Giants: Gross Profit Trends

Teva vs. Taro: A Decade of Financial Performance

In the competitive world of pharmaceuticals, Teva Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. have been key players. Over the past decade, Teva has consistently outperformed Taro in terms of gross profit, with Teva's figures peaking in 2016 at approximately 11.9 billion, while Taro's highest was around 779 million in the same year. However, both companies have faced challenges, with Teva's gross profit declining by about 41% from 2016 to 2022, and Taro experiencing a 66% drop in the same period. Notably, 2024 data for Teva is missing, indicating potential reporting delays or strategic shifts. This financial journey highlights the dynamic nature of the pharmaceutical industry, where market conditions and strategic decisions significantly impact profitability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025